SCHEMBL6340266

SCHEMBL6340266

C=C(C(=O)OCC)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
MAPT P10636 2/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
HPGD P15428 1/20 0.54
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54
PARP10 Q53GL7 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
SRD5A2 P31213 3/20 0.47
LTA4H P09960 1/20 0.47
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.47
THRB P10828 1/20 0.47
ERCC5 P28715 1/20 0.46
FEN1 P39748 1/20 0.46
MAPK14 Q16539 1/20 0.46
HDAC3 O15379 1/20 0.46
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316956 0.87 ALDH1A1 (0.69) ALDH1A1MAPTNPC1SMN1; SMN2LMNA
SCHEMBL22749297 0.87 AKR1C3 (0.55) ALDH1A1MAPTNPC1RAB9AHPGD
Ammonia Solution, Strong SCHEMBL27749588 0.85 ALDH1A1 (0.67) ALDH1A1MAPTNPC1SMN1; SMN2LMNA
SCHEMBL5059081 0.85 MAPT (0.55) ALDH1A1MAPTRAB9AHPGDSMN1; SMN2
SCHEMBL4739675 0.84 ALDH1A1 (0.57) ALDH1A1MAPTNPC1RAB9AHPGD
SCHEMBL21065617 0.84 MAPT (0.57) ALDH1A1MAPTRAB9AHPGDSMN1; SMN2
SCHEMBL8897038 0.82 PARP10 (0.53) ALDH1A1MAPTNPC1RAB9AHPGD
SCHEMBL28458575 0.82 ALDH1A1 (0.63) ALDH1A1MAPTNPC1SMN1; SMN2LMNA
SCHEMBL10878020 0.82 PARP10 (0.56) ALDH1A1MAPTNPC1RAB9AHPGD
SCHEMBL4113521 0.82 HDAC3 (0.53) ALDH1A1MAPTPARP10HTTHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113906068-A Resin composition for stereolithography 可乐丽则武齿科株式会社 2022-01-07 CN claimed
WO-2020246610-A1 RESIN COMPOSITION FOR OPTICAL SHAPING クラレノリタケデンタル株式会社 2020-12-10 WO claimed
CN-114072439-B Curable composition and resin composition for photofabrication comprising same 株式会社可乐丽 2024-05-14 CN disclosed
CN-113993497-B Curable composition and resin composition for photofabrication comprising same 株式会社可乐丽 2024-03-22 CN disclosed
CN-113677293-B Curable composition for dental restoration 可乐丽则武齿科株式会社 2023-10-10 CN disclosed
CN-116669679-A Adhesive composition for photo-molded article 可乐丽则武齿科株式会社 2023-08-29 CN disclosed
CN-115038730-A Resin composition for stereolithography 可乐丽则武齿科株式会社 2022-09-09 CN disclosed
CN-114828803-A Dental restorative composition 可乐丽则武齿科株式会社 2022-07-29 CN disclosed
CN-114430750-A Resin composition for stereolithography 可乐丽则武齿科株式会社 2022-05-03 CN disclosed
CN-114072439-A Curable composition and resin composition for stereolithography comprising same 株式会社可乐丽 2022-02-18 CN disclosed
CN-113993497-A Curable composition and resin composition for stereolithography comprising same 株式会社可乐丽 2022-01-28 CN disclosed
WO-2020246610-A1 RESIN COMPOSITION FOR OPTICAL SHAPING クラレノリタケデンタル株式会社 2020-12-10 WO disclosed
CN-111971318-A Photocurable resin composition 可乐丽则武齿科株式会社 2020-11-20 CN disclosed
WO-2020218446-A1 CURABLE COMPOSITION FOR DENTAL RESTORATION クラレノリタケデンタル株式会社 2020-10-29 WO disclosed
WO-2019189566-A1 PHOTOCURABLE RESIN COMPOSITION クラレノリタケデンタル株式会社 2019-10-03 WO disclosed
US-6967197-B2 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-22 US disclosed
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 US disclosed
WO-2003018019-A2 NEW USE OF CYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-06 WO disclosed
EP-1259499-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060808-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors MMP9, MMP1, MMP3 ALDH1A1 543/4885MAPT 4811/4885NPC1 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.